Pacer Advisors, Inc. Eli Lilly & CO Transaction History

Pacer Advisors, Inc.

$39 Billion
Q2 2024

A detailed history of Pacer Advisors, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Pacer Advisors, Inc. holds 68,017 shares of LLY stock, worth $59.7 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

68,017

Previous 64,304 5.77%

Holding current value

$59.7 Million

Previous $50 Million 23.1%

% of portfolio

0.16%

Previous 0.13%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$724.87 - $909.04 $2.69 Million - $3.38 Million	3,713 Added 5.77%	68,017 $61.6 Million
Q1 2024 May 10, 2024	SELL	$592.2 - $792.28 $8.17 Million - $10.9 Million	-13,802 Reduced 17.67%	64,304 $50 Million
Q4 2023 Jan 16, 2024	BUY	$525.19 - $619.13 $6.78 Million - $7.99 Million	12,904 Added 19.79%	78,106 $45.5 Million
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $1.45 Million - $2 Million	3,329 Added 5.38%	65,202 $35 Million
Q2 2023 Jul 12, 2023	BUY	$350.74 - $468.98 $1.02 Million - $1.37 Million	2,914 Added 4.94%	61,873 $29 Million
Q1 2023 May 02, 2023	BUY	$310.63 - $364.82 $17.5 Million - $20.5 Million	56,177 Added 2019.3%	58,959 $20.2 Million
Q4 2022 Feb 06, 2023	SELL	$321.55 - $374.67 $228,622 - $266,390	-711 Reduced 20.35%	2,782 $1.02 Million
Q3 2022 Oct 18, 2022	BUY	$296.48 - $337.87 $78,270 - $89,197	264 Added 8.18%	3,493 $1.13 Million
Q2 2022 Aug 12, 2022	SELL	$278.73 - $327.27 $10.5 Million - $12.3 Million	-37,604 Reduced 92.09%	3,229 $1.05 Million
Q1 2022 Apr 05, 2022	SELL	$234.69 - $291.66 $2.45 Million - $3.05 Million	-10,456 Reduced 20.39%	40,833 $11.7 Million
Q4 2021 Feb 03, 2022	BUY	$224.85 - $279.04 $546,385 - $678,067	2,430 Added 4.97%	51,289 $14.2 Million
Q3 2021 Oct 15, 2021	BUY	$221.6 - $272.71 $455,166 - $560,146	2,054 Added 4.39%	48,859 $11.3 Million
Q2 2021 Jul 21, 2021	BUY	$180.55 - $233.54 $574,871 - $743,591	3,184 Added 7.3%	46,805 $10.7 Million
Q1 2021 Apr 05, 2021	SELL	$164.32 - $212.72 $934,816 - $1.21 Million	-5,689 Reduced 11.54%	43,621 $8.15 Million
Q4 2020 Jan 20, 2021	SELL	$130.46 - $172.63 $1.43 Million - $1.9 Million	-10,984 Reduced 18.22%	49,310 $8.33 Million
Q3 2020 Oct 19, 2020	SELL	$146.22 - $169.13 $2.07 Million - $2.4 Million	-14,168 Reduced 19.03%	60,294 $8.93 Million
Q2 2020 Jul 29, 2020	BUY	$136.42 - $164.18 $10.2 Million - $12.2 Million	74,462 New	74,462 $12.2 Million
Q1 2020 Apr 23, 2020	SELL	$119.05 - $147.35 $11.5 Million - $14.2 Million	-96,685 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$106.92 - $132.43 $311,457 - $385,768	2,913 Added 3.11%	96,685 $12.7 Million
Q3 2019 Oct 10, 2019	BUY	$106.79 - $116.16 $488,243 - $531,083	4,572 Added 5.13%	93,772 $10.5 Million
Q2 2019 Aug 12, 2019	BUY	$110.79 - $129.32 $770,766 - $899,679	6,957 Added 8.46%	89,200 $9.88 Million
Q1 2019 Apr 10, 2019	BUY	$111.31 - $131.02 $9.15 Million - $10.8 Million	82,243 New	82,243 $10.7 Million
Q4 2018 Feb 13, 2019	SELL	$105.9 - $118.64 $5.42 Million - $6.08 Million	-51,226 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $553,797 - $692,149	6,450 Added 14.41%	51,226 $5.5 Million
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $572,594 - $657,160	7,564 Added 20.33%	44,776 $3.82 Million
Q1 2018 May 14, 2018	BUY	$74.21 - $87.6 $310,865 - $366,956	4,189 Added 12.69%	37,212 $2.88 Million
Q4 2017 Feb 14, 2018	BUY	$81.94 - $87.89 $770,809 - $826,781	9,407 Added 39.83%	33,023 $2.79 Million
Q3 2017 Nov 08, 2017	BUY	$77.07 - $85.54 $1.82 Million - $2.02 Million	23,616	23,616 $2.02 Million

Others Institutions Holding LLY

# of Institutions

3,872

Shares Held

751M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $834B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.

Account

Pacer Advisors, Inc. Eli Lilly & CO Transaction History